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Abstract
Background: Traditional randomized controlled trials are considered the gold standard for evaluating the efficacy of a 
treatment. However, in adherence research, limitations to this study design exist, especially when evaluating real-world 
applicability of an intervention. Although adherence interventions by community pharmacists have been tested, 
problems with internal and external validity have limited the usefulness of these studies, and further well-designed and 
well-conducted research is needed. We aimed to determine the real-world effectiveness of a community pharmacy 
adherence intervention using a robust study design. This novel design integrates cluster randomization and an 
outcome evaluation of medication adherence using a population-based administrative data source in the province of 
Saskatchewan, Canada.
Methods/Design: Community pharmacies from across the province of Saskatchewan, Canada were randomized to 
deliver an adherence intervention to their patients or usual care. Intervention pharmacies were trained to employ a 
practical adherence strategy targeted at new users of statin medications. While randomization and implementation of 
the intervention occurred at the community pharmacy level, the outcome analysis will occur at the level of the 
individual subjects. The primary outcome is the mean statin adherence among all eligible new users of statin 
medications. Secondary outcomes include the proportion of new statin users who exhibit adherence ≥80%, and 
persistence with statin use.
Discussion: This novel study design was developed to combine the rigor of a randomized trial with a pragmatic 
approach to implementing and capturing the results in a real-world fashion. We believe this approach can serve as an 
example for future study designs evaluating practice-based adherence interventions.
Trial Registration: ClinicalTrials.gov no. NCT00971412.
Introduction
Randomized controlled trials (RCT) are considered the
gold standard design for the evaluation of treatment effi-
cacy [1], and are increasingly being used for evaluating
interventions aimed at improving medication adherence
[2]. However, in adherence research, limitations to this
study design exist. First, traditional RCTs require that all
study participants are informed and consenting volun-
teers. This requirement likely pre-selects individuals who
are at a lower risk for non-adherence, particularly for
RCTs of behavioural interventions. Indeed, patients
enrolling in clinical trials may be systematically different
than those declining to participate[2,3]. In addition, when
traditional RCT designs are used, the same health care
professional is often forced to provide the adherence
intervention and 'usual care' concurrently [4,5]. Clearly,
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contamination is unavoidable when the same health prac-
titioner is providing the control and experimental condi-
tions simultaneously [3].
Because of their accessibility and frequent interactions
with patients, community pharmacists are considered
ideally situated to deliver interventions aimed at improv-
ing medication adherence [3]. However, adherence inter-
ventions by community pharmacists have not
consistently shown benefits [3,6]. One of the reasons may
be that these studies are often plagued with methodologi-
cal problems. Many studies do not report a power calcu-
lation, do not utilize proper randomization techniques or
allocation concealment, and most do not provide ade-
quate details of the intervention when reporting the
results [7]. Furthermore, generalizability of successful
interventions is often low because most health care pro-
fessionals do not have the time or resources to implement
complex study protocols [8-11]. As a result, little is
known about the extent to which community pharma-
cists can influence adherence in real world settings.
We describe the design of a study aimed at evaluating
the real-world effectiveness of an adherence intervention
provided by community pharmacies; the Community
Pharmacy Assisting in Total Cardiovascular Health
(CPATCH) study. This prospective study employs a novel
design that integrates cluster randomization with an eval-
uation of all at-risk patients using an administrative data-
base. This design presented herein was developed to
strengthen the external validity of research studies that
examine adherence interventions while maintaining the
high standards required for prospective clinical trials.
Although the general CPATCH strategy is intended to be
employable with all cardiovascular medications, this
study is focused on the prevention of non-adherence
among new users of statin medications. Statin medica-
tions were chosen for this initial study, as it is well known
t h a t  4 0 %  t o  5 0 %  o f  a l l  n e w  s t a t i n  u s e r s  b e c o m e  n o n -
adherent within the first year [12,13], and a sizeable pro-
portion discontinue the medication after only one dis-
pensation [14].
Methods
Recruitment of Community Pharmacies
In the Fall 2009, all community pharmacies across the
province of Saskatchewan (n = 357) were invited to enrol
in the CPATCH study. Advertisements were placed in
bulletins and newsletters distributed by provincial phar-
macy organizations. Also, individual letters were mailed
to all pharmacy owners/managers in the province and the
study investigators advertised in person at various local
pharmacy conferences and events.
Community pharmacies interested in enrolling were
directed to the study coordinating centre at the Univer-
sity of Saskatchewan to determine their eligibility. Phar-
macies were eligible for enrollment if: i) they filled at least
85 total statin prescriptions during a consecutive 6 week
period; ii) the owner/manager indicated that this adher-
ence intervention would be given priority over all other
study initiatives offered by the pharmacy staff; and iii) all
members of the pharmacy (dispensary) staff provided
informed consent.
Randomization
The CPATCH study employed a clustered randomized
trial design whereby community (retail) pharmacies were
randomized into one of two groups: an intervention
group that received training to provide the CPATCH
adherence strategy to their patients; and a usual care
group that did not receive any specialized adherence
training and will provide their patients with standard
care.
A computer generated randomization list, in permuted
blocks of 6, was created by an employee at the Drug
Information centre at the University of Saskatchewan
who is not an investigator in this study. Each randomly
allocated group assignment (intervention or usual care)
was individually sealed in sequential, opaque envelopes
and kept in the office of the Drug Information Centre.
Given the nature of the intervention, it was impossible for
the study investigators and pharmacy researchers (i.e.
participating pharmacies) to be blinded to the group
assignments; however, all study researchers were blinded
to the sequence generation, and all allocations were con-
cealed until the study group was assigned. Furthermore,
randomization was carried out in multiples of 6 (i.e., six
pharmacies were randomized at a time) to ensure that the
investigators had no opportunity to anticipate which
group a pharmacy would be allocated to.
The Intervention
Pharmacies (i.e. pharmacists and pharmacy technicians)
randomized to the intervention group received training
on how to implement the CPATCH support program
within their store; the control pharmacies did not receive
any training, and were intentionally not given any indica-
tion of the focus of the study intervention (adherence of
new statin users). Training on the CPATCH strategy was
provided through a 2.5 hour workshop delivered in a set-
ting outside the dispensary. Briefly, the training program
introduced a simple and coordinated strategy to consis-
tently identify and support patients at high risk for statin
non-adherence. The criteria used to identify individuals
at high-risk for non-adherence were based on epidemio-
logic observations of statin use. Specifically, individuals
receiving their first dispensation for a statin medication
have a 40%-50% of becoming non-adherent in the first
year of therapy [12,13]. Further, many patients will dis-
continue after only one dispensation [14]. These dispen-Evans et al. Trials 2010, 11:76
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sation patterns were used to provide objective evidence
about the risk for non-adherence associated with new
prescriptions for these medications. Also, these data were
used to justify our hypothesis that initial statin dispensa-
tion encounters are critical to the prevention of non-
adherence.
The CPATCH strategy was designed specifically to be
implemented into real-world community pharmacy prac-
tice without the need for additional resources or signifi-
cant changes to existing workflow procedures. As a
result, the program is flexible to each specific pharmacy.
The consistent elements of the overall CPATCH training
strategy are: i) routine identification of new users (those
in their first year of therapy) of statin medications as they
present for each dispensation; ii) consistent assessment
for barriers to non-adherence at every dispensation for
at-risk patients (new users); iii) a paradigm shift from tra-
d i t i o n a l  c o u n s e l l i n g  t o  a n  a p p r o a c h  t h a t  f o c u s e s  o n
patient preparation and reassurance; preparation for the
negative messages about statins they will likely hear in the
coming months and reassurance that this medication is
backed by objective evidence, and iv) a commitment by
pharmacy staff to actively respond to identified adher -
ence barriers such as cost, intolerance, lack of knowledge,
or beliefs about the medication. The focus of this strategy
is to lower the incidence of non-adherence rather than
remedy those patients with established non-adherence.
Subjects
Intervention pharmacies will identify patients within the
first year of statin therapy through dispensation records
and face-to-face encounters. Although intervention phar-
macies will target all statin users within their first year of
therapy, data will only be collected on those subjects who:
i) receive a new statin prescription from a study phar-
macy (intervention or control) during the observation
period; ii) have no statin fills recorded during the year
prior to the index prescription (first fill for a statin medi-
cation during the study observation period); and iii) have
been continuously enrolled as a Saskatchewan Drug Plan
beneficiary for at least 365 days prior to the index pre-
scription. These study subjects will be identified indepen-
dently by personnel from the Saskatchewan Ministry of
Health and all outcome data will be collected at the
administrative database level (see "Follow-up").
The observation period for each pharmacy will begin
two weeks after their training session. This two week lag
period will be used to allow each staff to implement the
strategy and resolve any issues with the help of the
CPATCH investigators. To ensure consistency between
groups, usual care pharmacies were assigned a start date
that matched the date of an intervention pharmacy falling
most closely in the order of randomization. As a result, in
each permuted block of six randomized pharmacies,
three pairs (one control and one intervention) of stores
will share the same start date.
Follow-up
All patient information and outcome data will be col-
lected from administrative databases maintained by the
Saskatchewan Ministry of Health (Sask Heath). Sask
Health maintains a registry and several databases con-
taining health-services records such as prescription drug
data, hospital services data, and physician services data
(Table 1). Health services information captured by dis-
tinct databases can be linked at the patient level through
a unique identification number for each individual. These
databases have served as the basis for many observational
studies because they capture data on the vast majority of
Saskatchewan residents [15-18]. For this study, the data-
bases will be used to capture health services utilization
(prescriptions, physician visits and hospitalizations)
including diagnoses on all eligible subjects.
Table 1: Relevant Data Elements Available from 
Saskatchewan Health Databases 
Database Available Data
Prescription Drug Patient information
Drug information
Prescriber information
Dispensing pharmacy 
information
Cost information
Hospital Services Patient information
Diagnostic and procedure 
information (based on ICD-
10-CAa and CCIb)
Admission and discharge 
dates
Length of hospital stay
Physician Services Patient information
Physician information
Diagnostic information (3 
digit ICD-9c code)
Billing information
Insurance registry Beneficiary information 
(effective date, end date, sex, 
age, residence)
a. International Statistical Classification of Disease and Related 
Health Problems, Tenth Revision, Canada [35]
b. Canadian Classification of Health Interventions [36]
c. International Classification of Disease, Ninth RevisionEvans et al. Trials 2010, 11:76
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All Saskatchewan residents are eligible for provincial
health insurance coverage, except inmates of federal pen-
itentiaries and members of the Royal Canadian Mounted
Police and Canadian Forces (less than 1% of the Saskatch-
ewan population). All health insurance beneficiaries are
eligible for Saskatchewan Drug Plan benefits except those
who receive these benefits from another government
agency, primarily registered Indians (about 9% of the
population). Therefore about 10% of the Saskatchewan
population is ineligible for the study because of no or
incomplete capture of health services information.
The researchers will provide Sask Health with the list of
participating pharmacies and their specific Saskatchewan
Drug Plan identifiers (i.e., provider identifier), and enrol-
ment dates. Sask Health personnel will extract all statin
prescriptions dispensed from the participating pharma-
cies during the 18 months following the pharmacy's
enrolment date. The individuals receiving these prescrip-
tions will form the pool of potential new statin-users. The
prescription histories of the potential pool members will
be reviewed to determine which subjects are new statin-
users. Hospital, physician and prescription information
for eligible new statin-users will be compiled and de-
identified prior to release to the researchers for analysis.
It is estimated that each pharmacy will need six months
to accrue their sample size of new statin users, thereby
allowing 12 months for follow up. However, because it
will not be possible to determine when each pharmacy's
sample size has been met, data will be collected on all
new-users presenting to each pharmacy throughout the
observation period. Subjects will be followed from one
year prior to their index prescription until the end of the
pharmacy's observation period, death, or loss of benefi-
ciary status, whichever is sooner.
Outcomes
Although community pharmacies are the unit of random-
ization, our primary outcome is the mean statin adher-
ence among all eligible new users of statin medications
who have been followed up for at least 6 months past
their index prescription. This primary outcome will be
measured at the individual level. All statin dispensations
for each subject will be captured by the prescription drug
plan database and mean adherence will be measured
using the proportion of days covered (PDC) [19,20],
adjusted for any days that a subject may be hospitalized
during the observation period. The PDC is calculated by
taking the sum of the days' supply for all statin prescrip-
tion fills during the study period, divided by the number
of days of observation. Study participants who have statin
dispensations from non-study pharmacies will be cap-
tured and accounted for using methods previously pub-
lished [21]. Secondary outcomes include the proportion
of new statin users who exhibit adherence (PDC) ≥80%,
and the persistence with statin use among patients with a
minimum of 12 months of follow up. Persistence is
defined as the number of days from the index prescrip-
tion to the earliest occurrence of study end date or date of
discontinuation (assumed when a refill is not obtained
within 102 days of finishing the estimated supply) [22,23].
Only those subjects with a minimum of 6 months of fol-
low-up will be included in the secondary analyses.
Sample Size
Using data from a previous observational study evaluat-
ing one-year statin adherence of new users at 34 different
community pharmacies in Saskatchewan [21], we were
able to estimate an intracluster (or intraclass) correlation
coefficient (ICC) of 0.0143, and determine that mean sta-
tin adherence in this population was 0.71 (SD 0.13). Thus,
in order to detect a 15% improvement in mean adher-
ence, considered to be clinically important [24,25], 270
subjects would be required in each group to detect a dif-
ference of approximately 15% with 80% power at a p <
0.05. The community pharmacies enrolled in CPATCH
are expected to accrue a minimum of 25 subjects over a 6
month period. As a result, 22 clusters (pharmacies) are
calculated as needed, but 30 will actually be enrolled as
the planned statistical analysis requires a minimum of 15
clusters within each group [26].
Statistical Methods
Baseline characteristics will be compared between groups
using both cluster and individual-level variables (Table 2).
To determine the effect of the intervention, mean adher-
ence will be measured at one year using generalized esti-
mating equations (GEE) with an exchangeable correlation
matrix and robust standard errors, with individuals as the
analytical unit [27]. Both univariate and multivariable
models will be developed based on individual and phar-
macy-level variables considered statistically significant (P
< 0.10), or clinically important (e.g. age, sex) (Table 2). All
first order interactions will be tested.
Two secondary endpoints, the proportion of new statin
users who exhibit optimal adherence (≥80%) at one-year
and mean persistence will be measured on an individual
level and analyzed using GEE with an exchangeable cor-
relation matrix and robust standard errors. All analyses
will be intention-to-treat, and will include any pharma-
cies that have withdrawn, as well as any individual sub-
jects who are no longer beneficiaries of the Saskatchewan
Drug Plan (due to death or coverage termination). Mean
imputation will be used for subjects or pharmacies lost-
to-follow-up.
Ethics approval for the study protocol was obtained
from the University of Saskatchewan Biomedical Ethics
Board (09-135). The study is registered at ClinicalTri-
als.gov no. NCT00971412.Evans et al. Trials 2010, 11:76
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Table 2: Individual and Pharmacy Level Variables Available for Multivariable Analysis
Variable Description Database Source
Individual Level
Sex Sex of subject Insurance registry
Age Age of subject at index date (calculated using date of birth) Insurance registry
Income security benefits Patient receives income security benefit (a proxy for 
socioeconomic status)
Prescription drug
Concurrent medications Concurrent medications use during one year prior to subject's 
index date, and for the first 6 months of the study observation 
period.
Prescription Drug
Beta blockers
Angiotensin converting enzyme inhibitors
ASA
Oral hypoglycemics
Prior cardiovascular event Cardiovascular event(s) in one year prior to subject's index date 
(Based in ICD-10-CA classifications)
Hospital Services
Myocardial infarction (I21. - I23.)
Stroke (all causes) (I60. - I64.)
Transient ischemic attack (G45.0)
Unstable angina (I20.0)
Other ischemic heart disease (I24. - I25.)
Revascularization procedures
PTCA (1.IJ.50, 1.IJ.57.GQ, 1.IL.35), CABG (1.IJ.76)
Coronary Angiography (3.IP.10)
Study cardiovascular event Cardiovascular event(s) during study period (Based in ICD-10-CA 
classifications)
Hospital Services
Myocardial infarction (I21. - I23.)
Stroke (all causes) (I60. - I64.)
Transient ischemic attack (G45.0)
Unstable angina (I20.0)
Other ischemic heart disease (I24. - I25.)
Revascularization procedures
PTCA (1.IJ.50, 1.IJ.57.GQ, 1.IL.35), CABG (1.IJ.76)
Coronary Angiography (3.IP.10)
Chronic disease score Chronic disease score (measure of chronic disease status derived 
from population-based automated pharmacy data) [37]
Prescription Drug
Prior hospitalizations Number of hospitalizations in one year prior to subject's index date Hospital Services
Study hospitalizations Number of hospitalizations during study observation period Hospital ServicesEvans et al. Trials 2010, 11:76
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Discussion
Medication non-adherence is a global problem [28] that
consumes substantial financial health care resources [29],
and has been recognized as a predictor of negative
patient outcomes [17,30]. Non-adherence is complicated
and multifactorial [31], and health interventions that are
aimed at improving it are often not evaluated using prag-
matic study designs. Recognizing this, we have utilized a
novel study design evaluating an intervention involving
community pharmacies, aimed at improving medication
adherence.
A CRT design was selected for this study for two rea-
sons. First, the intervention is intended for implementa-
tion at the community pharmacy level, so it is logical that
community pharmacies would be the unit of randomiza-
tion. Second, this design will lessen the risk for experi-
mental contamination because pharmacists will not be
forced to provide intervention and usual care activities at
the same time [32]. We can not rule out the potential for
the Hawthorne effect [33] within the usual care pharma-
cies; however , the effect is likely minimal as this group
was intentionally not given any indication of the focus of
the study intervention (adherence of new statin users).
Also, this design will eliminate the need to recruit, obtain
consent, and randomize individual patients, which is
often impractical in typical community pharmacy set-
tings.
We were prudent in following the guidelines for cluster
randomized trials outlined in the CONSORT statement
[34], ensuring that the risk of contamination between
groups will be minimized, while maintaining the integrity
of the experimental group comparison. Because the inter-
vention will be evaluated in all new statin users present-
ing to each store, it will enhance the external validity of
this study. Also, by ensuring all patient data are collected
at arms length (by the Saskatchewan Ministry of Health),
pharmacists can implement the adherence support strat-
egy on all patients without the administrative burden of
obtaining patient consent and collecting study specific
information.
In addition, we have also provided the ICC used in esti-
mating our sample size. To our knowledge, this ICC is the
first one to be published in this particular field of
research. We hope this value will prove useful in the
d e s i g n  o f  f u t u r e  s t u d i e s  a s  w e l l  a s  e n c o u r a g e  o t h e r
researchers, especially in the area of medication adher-
ence, to share their ICCs or cluster specific event rates.
In conclusion, we have presented, in detail, the design
of the CPATCH study. Our approach combines the rigor
of a randomized trial with a pragmatic approach to
implementing and recording the results in a real-world
fashion. We believe this approach can serve as an exam-
ple of study design for the evaluation of future practice-
based adherence interventions in large randomized trials.
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Physician visits Number of physician visits during and prior to observation Physician Services
Pharmacy Level
Pharmacy Type Indicates the type of pharmacy (mass merchandise, chain/grocery, 
independent) [38]
Investigators to 
categorize
Pharmacy Location Rural (population < 10,000) Investigators to 
categorize
Regional (population 10,000 - 100,000)
Urban (population > 100,000)
Prescription Volume Mean number of new statin prescriptions filled monthly (proxy 
measure for prescription volume)
Prescription Drug
Pharmacist Coverage Pharmacist overlap or single pharmacist Pharmacy survey
Technician Support Pharmacy technician support Pharmacy survey
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